AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37806314 — intervention group
Group type: EXPERIMENTAL
Intervention: HU6 300 mg
Number of subjects: 80
Study 37806314 — intervention group
Group type: EXPERIMENTAL
Intervention: HU6 450 mg
Number of subjects: 80
Study 37806314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 37806314 — intervention group
Group type: EXPERIMENTAL
Intervention: HU6 (combined)
Number of subjects: 80
Study 37806314 — intervention group
Group type: EXPERIMENTAL
Intervention: HU6
Number of subjects: 80
Study 37806333 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting balloon (DEB) in the side branch
Number of subjects: 500
Study 37806333 — intervention group
Group type: COMPARATOR
Intervention: Drug-eluting stent (DES) in the side branch
Number of subjects: 500
Study 37806372 — intervention group
Group type: EXPERIMENTAL
Intervention: LT-02 1.6 g BID
Number of subjects: 466
Study 37806372 — intervention group
Group type: COMPARATOR
Intervention: Mesalamine 500 mg TID
Number of subjects: 466
Study 37806372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 466
Study 37806372 — intervention group
Group type: COMPARATOR
Intervention: LT-02 0.8 g QID
Number of subjects: 466
Study 37806620 — intervention group
Group type: EXPERIMENTAL
Intervention: ECPR-based approach
Number of subjects: 256
Study 37806620 — intervention group
Group type: COMPARATOR
Intervention: Standard approach
Number of subjects: 256
Study 37806650 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin plus a Cook balloon
Number of subjects: 150
Study 37806650 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol plus a Cook balloon
Number of subjects: 150
Study 37806651 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg daily
Number of subjects: 47
Study 37806651 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine 30 mg extended-release daily
Number of subjects: 47
Study 37806794 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft resin trays
Number of subjects: 552
Study 37806794 — intervention group
Group type: COMPARATOR
Intervention: Hard resin trays
Number of subjects: 552
Study 37807000 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple Linear Regression Model (SLM)
Number of subjects: 0
Study 37807000 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed Effects Model (MEM)
Number of subjects: 0
Study 37807000 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed Effects Model (MEM) with inter-measurement variation
Number of subjects: 0
Study 37807004 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated myocardial flow reserve (iMFR) assessment
Number of subjects: 1044
Study 37807004 — intervention group
Group type: EXPERIMENTAL
Intervention: Focally impaired perfusion
Number of subjects: 1044
Study 37807004 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusely impaired perfusion
Number of subjects: 1044
Study 37807032 — intervention group
Group type: EXPERIMENTAL
Intervention: mini percutaneous nephrolithotomy (mPNL)
Number of subjects: 48
Study 37807032 — intervention group
Group type: COMPARATOR
Intervention: JJ stent placement followed by second session flexible ureterorenoscopy (f-URS)
Number of subjects: 48
Study 37807032 — intervention group
Group type: COMPARATOR
Intervention: flexible ureterorenoscopy (f-URS)
Number of subjects: 48
Study 37807179 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g TXA bolus
Number of subjects: 422
Study 37807179 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g bolus + 1 g/8 hours TXA infusion
Number of subjects: 422
Study 37807179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 422
Study 37807937 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferiprone
Number of subjects: 142
Study 37807937 — intervention group
Group type: COMPARATOR
Intervention: Deferoxamine
Number of subjects: 142
Study 37807952 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 37808274 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mL safety syringe (SSy)
Number of subjects: 214
Study 37808274 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mL auto-injector (AI)
Number of subjects: 214
Study 37808500 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES-RT + FES
Number of subjects: 33
Study 37808500 — intervention group
Group type: COMPARATOR
Intervention: PMT + FES
Number of subjects: 33
Study 37808864 — intervention group
Group type: EXPERIMENTAL
Intervention: EP-3533 (type 1 collagen probe)
Number of subjects: 0
Study 37808864 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan treatment
Number of subjects: 0
Study 37808864 — intervention group
Group type: COMPARATOR
Intervention: Excised human lung tissue with RILI
Number of subjects: 0
Study 37808932 — intervention group
Group type: EXPERIMENTAL
Intervention: Irritable bowel syndrome (IBS) diagnosis according to ROME IV criteria
Number of subjects: 0
Study 37809311 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS (2 mA) during CCT
Number of subjects: 59
Study 37809311 — intervention group
Group type: EXPERIMENTAL
Intervention: tACS (5 Hz) during CCT
Number of subjects: 59
Study 37809311 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation during CCT
Number of subjects: 59
Study 37809334 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (US) phacoemulsification
Number of subjects: 74
Study 37809334 — intervention group
Group type: COMPARATOR
Intervention: Nanolaser technique
Number of subjects: 74
Study 37810529 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition to virtual visits
Number of subjects: 1313
Study 37810529 — intervention group
Group type: COMPARATOR
Intervention: In-person program delivery
Number of subjects: 1313
Study 37810589 — intervention group
Group type: EXPERIMENTAL
Intervention: Faricimab 6.0 mg
Number of subjects: 1282
Study 37810589 — intervention group
Group type: COMPARATOR
Intervention: Aflibercept 2.0 mg
Number of subjects: 1282
Study 37810620 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain-IT training concept with Senso Flex exergaming system for 12 weeks
Number of subjects: 18
Study 37810620 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 18
Study 37810917 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants (Nicotinamide riboside and Pterostilbene)
Number of subjects: 40
Study 37810917 — intervention group
Group type: EXPERIMENTAL
Intervention: Coconut oil
Number of subjects: 40
Study 37810917 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants + Coconut oil
Number of subjects: 40
Study 37810917 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study 37810925 — intervention group
Group type: EXPERIMENTAL
Intervention: SNAQ food-recognition mobile application
Number of subjects: 0
Study 37810925 — intervention group
Group type: COMPARATOR
Intervention: Traditional dietary assessment methods (food records, food frequency questionnaires, 24-hour dietary recalls)
Number of subjects: 0
Study 37810934 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptation of survey questions designed for cisgender men to include TGNB participants and partners
Number of subjects: 0
Study 37811343 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib plus endocrine therapy (ET)
Number of subjects: 0
Study 37811343 — intervention group
Group type: COMPARATOR
Intervention: Endocrine therapy (ET) alone
Number of subjects: 0
Study 37811523 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil (20 mg)
Number of subjects: 65
Study 37811523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 37811525 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy meal replacement plan (MRP) ~810 kcal/day
Number of subjects: 27
Study 37811538 — intervention group
Group type: EXPERIMENTAL
Intervention: EORTC/NCIC study (NCT00006353)
Number of subjects: 11
Study 37811538 — intervention group
Group type: EXPERIMENTAL
Intervention: EF-14 (NCT00916409)
Number of subjects: 11
Study 37811538 — intervention group
Group type: EXPERIMENTAL
Intervention: CeTeG (NCT01149109)
Number of subjects: 11
Study 37811538 — intervention group
Group type: COMPARATOR
Intervention: Other trials (not specified)
Number of subjects: 11
Study 37811598 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder training
Number of subjects: 2007
Study 37811634 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin 600 mg once daily with limertinib 160 mg (Part A)
Number of subjects: 48
Study 37811634 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg twice daily with limertinib 80 mg (Part B)
Number of subjects: 48
Study 37811665 — intervention group
Group type: COMPARATOR
Intervention: Erector spinae plane block (ESPB)
Number of subjects: 3973
Study 37811711 — intervention group
Group type: COMPARATOR
Intervention: Atypical antipsychotics
Number of subjects: 7014
Study 37811711 — intervention group
Group type: COMPARATOR
Intervention: Neurohormones
Number of subjects: 7014
Study 37811711 — intervention group
Group type: COMPARATOR
Intervention: ADHD-related medications
Number of subjects: 7014
Study 37811711 — intervention group
Group type: COMPARATOR
Intervention: Antidepressants
Number of subjects: 7014
Study 37811993 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26 mosaic vaccine regimen
Number of subjects: 0
Study 37812227 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 37812229 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom questionnaire (Patient Symptom Survey)
Number of subjects: 353
Study 37812229 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesic administration
Number of subjects: 353
Study 37812229 — intervention group
Group type: EXPERIMENTAL
Intervention: Sepsis diagnosis
Number of subjects: 353
Study 37812229 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 353
Study 37812229 — intervention group
Group type: EXPERIMENTAL
Intervention: Being mechanically ventilated
Number of subjects: 353
Study 37812229 — intervention group
Group type: EXPERIMENTAL
Intervention: Family visits
Number of subjects: 353
Study 37812229 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 353
Study 37812242 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilator-associated pneumonia (VAP)
Number of subjects: 1060
Study 37812242 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilator-associated tracheobronchitis (VAT)
Number of subjects: 1060
Study 37812242 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-acquired pneumonia (HAP)
Number of subjects: 1060
Study 37812242 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU hospital-acquired pneumonia (ICU-HAP)
Number of subjects: 1060
Study 37812242 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilator-associated HAP (VHAP)
Number of subjects: 1060
Study 37812242 — intervention group
Group type: COMPARATOR
Intervention: Overall mortality rates
Number of subjects: 1060
Study 37812242 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiological identification
Number of subjects: 1060
Study 37812272 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma Focused Cognitive Behavioral Therapy (TF-CBT)
Number of subjects: 610
Study 37812272 — intervention group
Group type: COMPARATOR
Intervention: Psychosocial Counseling (PC+)
Number of subjects: 610
Study 37812306 — intervention group
Group type: EXPERIMENTAL
Intervention: Active use of PROs with built-in alert-algorithm (Intervention Arm - IA)
Number of subjects: 228
Study 37812306 — intervention group
Group type: COMPARATOR
Intervention: Standard procedure for handling of side effects (Control Arm - CA)
Number of subjects: 228
Study 37812307 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced salt solution (BSS) supplementation before intraocular lens (IOL) implantation and before the end of surgery.
Number of subjects: 95
Study 37812307 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal AL)
Number of subjects: 95
Study 37812381 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic norepinephrine 0 µg/kg/min
Number of subjects: 175
Study 37812381 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic norepinephrine 0.025 µg/kg/min
Number of subjects: 175
Study 37812381 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic norepinephrine 0.05 µg/kg/min
Number of subjects: 175
Study 37812381 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic norepinephrine 0.075 µg/kg/min
Number of subjects: 175
Study 37812381 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic norepinephrine 0.1 µg/kg/min
Number of subjects: 175
Study 37812381 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic norepinephrine (all dosages)
Number of subjects: 175
Study 37812429 — intervention group
Group type: EXPERIMENTAL
Intervention: XEN1101 25 mg
Number of subjects: 325
Study 37812429 — intervention group
Group type: EXPERIMENTAL
Intervention: XEN1101 20 mg
Number of subjects: 325
Study 37812429 — intervention group
Group type: EXPERIMENTAL
Intervention: XEN1101 10 mg
Number of subjects: 325
Study 37812429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 325
Study 37812476 — intervention group
Group type: EXPERIMENTAL
Intervention: PELA/BZ/Dex
Number of subjects: 14
Study 37812518 — intervention group
Group type: EXPERIMENTAL
Intervention: 131I-MIP-1095 (50 mCi in cohort 1, 75 mCi in cohort 2)
Number of subjects: 9
Study 37812518 — intervention group
Group type: EXPERIMENTAL
Intervention: 131I-MIP-1095
Number of subjects: 9
Study 37812653 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable Cardioverter Defibrillator (ICD)
Number of subjects: 0
Study 37812653 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 0
Study 37812653 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ICD or CRT)
Number of subjects: 0
Study 37812679 — intervention group
Group type: EXPERIMENTAL
Intervention: Darolutamide 600 mg plus ADT and docetaxel
Number of subjects: 54
Study 37812679 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus ADT and docetaxel
Number of subjects: 54
Study 37812772 — intervention group
Group type: EXPERIMENTAL
Intervention: Aroxybutynin and Atomoxetine
Number of subjects: 0
Study 37812772 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 37813304 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous oxytocin infusion (16 hours, with a 4 hours pause in between infusions)
Number of subjects: 153
Study 37813304 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous oxytocin infusion
Number of subjects: 153
Study 37813418 — intervention group
Group type: EXPERIMENTAL
Intervention: Early antihypertensive treatment started within 24-48 hours aimed at reducing systolic blood pressure by 10%-20% within the first 24 hours and achieving mean blood pressure <140/90 mm Hg within seven days.
Number of subjects: 4810
Study 37813418 — intervention group
Group type: COMPARATOR
Intervention: Delayed antihypertensive treatment starting on day 8 aimed at achieving mean blood pressure <140/90 mm Hg.
Number of subjects: 4810
Study 37813418 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment group
Number of subjects: 4810
Study 37813418 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment group
Number of subjects: 4810
Study 37813479 — intervention group
Group type: COMPARATOR
Intervention: Vaginal brachytherapy
Number of subjects: 294
Study 37813479 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 294
Study 37813479 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Number of subjects: 294
Study 37813527 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable motion-based platform for functional assessments
Number of subjects: 100
Study 37813532 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking status (smokers vs non-smokers)
Number of subjects: 400
Study 37813532 — intervention group
Group type: EXPERIMENTAL
Intervention: Luminex xMAP-based multiplex immunoassay for inflammatory mediators and cytokines
Number of subjects: 400
Study 37813532 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung function measurements and chest CT examinations
Number of subjects: 400
Study 37813562 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitively impaired group (Montreal Cognitive Assessment score <26)
Number of subjects: 239
Study 37813562 — intervention group
Group type: COMPARATOR
Intervention: Normal cognition group (Montreal Cognitive Assessment score ≥26)
Number of subjects: 239
Study 37813560 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial appendage closure (LAAC)
Number of subjects: 1053
Study 37813745 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 720
Study 37813841 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (n=73)
Number of subjects: 145
Study 37813841 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet (n=72)
Number of subjects: 145
Study 37813841 — intervention group
Group type: COMPARATOR
Intervention: Fat-responders receiving high-carbohydrate diet
Number of subjects: 145
Study 37813841 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate-responders receiving high-fat diet
Number of subjects: 145
Study 37813841 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-responders receiving high-carbohydrate diet
Number of subjects: 145
Study 37813884 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry immersion for 5 days
Number of subjects: 18
Study 37813959 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinutuximab beta (continuous infusion over 10 days of each cycle, for up to five cycles)
Number of subjects: 40
Study 37814020 — intervention group
Group type: EXPERIMENTAL
Intervention: Red meat meal consumption in women with RA
Number of subjects: 44
Study 37814020 — intervention group
Group type: COMPARATOR
Intervention: Red meat meal consumption in matched control group (women without RA)
Number of subjects: 44
Study 37814061 — intervention group
Group type: EXPERIMENTAL
Intervention: pembrolizumab as standard of care
Number of subjects: 50
Study 37814121 — intervention group
Group type: EXPERIMENTAL
Intervention: E7820, an anti-cancer sulfonamide
Number of subjects: 0
Study 37814129 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg escitalopram (n=17)
Number of subjects: 32
Study 37814129 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=15)
Number of subjects: 32
Study 37814224 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed hemodynamic therapy (GDHT)
Number of subjects: 75
Study 37814224 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 75
Study 37814266 — intervention group
Group type: EXPERIMENTAL
Intervention: PA-telecoaching program (smartphone application with individual targets and feedback for 6 months, self-monitoring with a step counter for 9 months)
Number of subjects: 73
Study 37814266 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 73
Study 37814285 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcopenia nursing guidance mobile application
Number of subjects: 120
Study 37814306 — intervention group
Group type: EXPERIMENTAL
Intervention: Fotagliptin
Number of subjects: 458
Study 37814306 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin
Number of subjects: 458
Study 37814306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 458
Study 37814306 — intervention group
Group type: COMPARATOR
Intervention: Fotagliptin vs Placebo
Number of subjects: 458
Study 37814306 — intervention group
Group type: COMPARATOR
Intervention: Alogliptin vs Placebo
Number of subjects: 458
Study 37814306 — intervention group
Group type: COMPARATOR
Intervention: Fotagliptin vs Alogliptin
Number of subjects: 458
Study 37814306 — intervention group
Group type: EXPERIMENTAL
Intervention: Fotagliptin and Alogliptin
Number of subjects: 458
Study 37814306 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 458
Study 37814388 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-body irradiation with 450 nm blue light
Number of subjects: 87
Study 37814388 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-body irradiation with 415 nm blue light
Number of subjects: 87
Study 37814388 — intervention group
Group type: COMPARATOR
Intervention: Sham irradiation
Number of subjects: 87
Study 37814541 — intervention group
Group type: EXPERIMENTAL
Intervention: Olme/Amlo/Rosu 20/5/5 mg
Number of subjects: 106
Study 37814541 — intervention group
Group type: EXPERIMENTAL
Intervention: Olme/Amlo/Rosu 20/5/10 mg
Number of subjects: 106
Study 37814541 — intervention group
Group type: COMPARATOR
Intervention: Amlo/Olme 20/5 mg
Number of subjects: 106
Study 37814607 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 60
Study 37814607 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 60
Study 37814832 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine maintenance therapy
Number of subjects: 0
Study 37814892 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive systolic blood pressure (SBP) lowering (target 110 to <130 mm Hg)
Number of subjects: 8259
Study 37814892 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (SBP target 130 to <150 mm Hg)
Number of subjects: 8259
Study 37814912 — intervention group
Group type: EXPERIMENTAL
Intervention: PB biopsy and preimplantation genetic testing for aneuploidy (PGT-A)
Number of subjects: 396
Study 37814912 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PB biopsy and PGT-A)
Number of subjects: 396
Study 37815031 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban in patients with thrombocytopenia
Number of subjects: 0
Study 37815031 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 37815037 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading dose alone regimen
Number of subjects: 3020
Study 37815037 — intervention group
Group type: COMPARATOR
Intervention: Loading dose plus maintenance dose regimen
Number of subjects: 3020
Study 37815037 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-dose regimen
Number of subjects: 3020
Study 37815037 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose regimen over 24 hours
Number of subjects: 3020
Study 37815037 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) maintenance regimen
Number of subjects: 3020
Study 37815037 — intervention group
Group type: COMPARATOR
Intervention: Standard intramuscular (IM) maintenance regimen
Number of subjects: 3020
Study 37815037 — intervention group
Group type: EXPERIMENTAL
Intervention: Short maintenance regimen
Number of subjects: 3020